Portal de Periódicos da CAPES

UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors

2019; Cell Press; Volume: 176; Issue: 3 Linguagem: Inglês

10.1016/j.cell.2018.11.024

1097-4172

Ron D. Jachimowicz, Filippo Beleggia, Jörg Isensee, Bhagya Bhavana Velpula, Jonas Goergens, Matías A. Bustos, Markus Alexander Doll, Anjana Shenoy, Cintia Checa-Rodríguez, Janica L. Wiederstein, Keren Baranes‐Bachar, Christoph Bartenhagen, Falk Hertwig, Nizan Teper, Tomohiko Nishi, Anna Schmitt, Felix Distelmaier, Hermann‐Josef Lüdecke, Beate Albrecht, Marcus Krüger, Björn Schumacher, Tamar Geiger, Dave S.�B. Hoon, Pablo Huertas, Matthias Fischer, Tim Hucho, Martin Peifer, Yael Ziv, Hans Christian Reinhardt, Dagmar Wieczorek, Yosef Shiloh,

Genomics and Chromatin Dynamics

Genomic instability can be a hallmark of both human genetic disease and cancer. We identify a deleterious UBQLN4 mutation in families with an autosomal recessive syndrome reminiscent of genome instability disorders. UBQLN4 deficiency leads to increased sensitivity to genotoxic stress and delayed DNA double-strand break (DSB) repair. The proteasomal shuttle factor UBQLN4 is phosphorylated by ATM and interacts with ubiquitylated MRE11 to mediate early steps of homologous recombination-mediated DSB repair (HRR). Loss of UBQLN4 leads to chromatin retention of MRE11, promoting non-physiological HRR activity in vitro and in vivo. Conversely, UBQLN4 overexpression represses HRR and favors non-homologous end joining. Moreover, we find UBQLN4 overexpressed in aggressive tumors. In line with an HRR defect in these tumors, UBQLN4 overexpression is associated with PARP1 inhibitor sensitivity. UBQLN4 therefore curtails HRR activity through removal of MRE11 from damaged chromatin and thus offers a therapeutic window for PARP1 inhibitor treatment in UBQLN4-overexpressing tumors.